Insmed Discontinues Development of Skin Condition Drug After Mid-Stage Study Miss
Insmed announced it will discontinue development of brensocatib, its investigational therapy for hidradenitis suppurativa, after the drug failed to meet the primary efficacy endpoint in a mid‑stage trial. The study aimed to reduce painful nodules in patients with the chronic inflammatory skin disease but fell short of its goal. Although the trial did not demonstrate the expected clinical benefit, safety data showed no new concerns. Insmed plans to present the full results at a forthcoming scientific meeting.
FDA-Approved Drug Manufacturing Deals Shift to Europe
In 2025, U.S. contract manufacturing deals for FDA‑approved drugs fell sharply, while Europe recorded more than three times the U.S. volume. Despite a 15% U.S. tariff on EU pharmaceuticals, major U.S. firms such as Johnson & Johnson and Vertex invested...
Gilead to Buy Germany’s Tubulis for up to $5 Billion to Boost Cancer Pipeline
Gilead Sciences announced it will acquire Germany‑based Tubulis GmbH for up to $5 billion, adding the biotech’s antibody‑drug conjugate (ADC) platform to its portfolio. The deal follows Gilead’s recent $7.8 billion purchase of Arcellx and a $2 billion acquisition of Ouro Medicines, reflecting...
Rethinking eCOA: Why Earlier Input by Data Managers Is Needed
Electronic clinical outcome assessment (eCOA) is a mature technology, yet its adoption lags behind other digital trial tools. The traditional siloed approach forces data managers to engage only after data collection, inflating costs and extending timelines. Involving data managers early...
Neurocrine Expands Into Metabolic Diseases with $2.9 Billion Soleno Buyout
Neurocrine Biosciences announced a $2.9 billion cash acquisition of Soleno Therapeutics, marking its first foray into metabolic diseases. The deal secures Vykat XR, the inaugural FDA‑approved treatment for hyperphagia in Prader‑Willi syndrome, expanding Neurocrine’s rare‑disease portfolio. Soleno shareholders receive $53 per share,...
Parkinson’s Awareness Month 2026: Alpha Synuclein Emerges as Leading Target in Disease Pipeline
During Parkinson’s Awareness Month 2026, GlobalData reports a clear shift in the drug development landscape toward alpha‑synuclein as the top therapeutic target. While 53% of the 64 approved Parkinson’s drugs still focus on dopamine receptors, the pipeline now includes 62...
Biopharma Catalysts in Q2 2026 Signal High-Profile Approval Decisions and Rising Competition
The Q2 2026 catalyst slate highlights several high‑profile FDA decisions that could reshape the breast‑cancer and obesity markets. Replimune plans a BLA resubmission for vusolimogene oderparevec with a PDUFA date of April 10, 2026, while Arvinas expects a June 5, 2026 decision on vepdegestrant, which showed...
Rare Disease Advocacy Group Urges Trump Administration to Restore FDA Clarity
A coalition of nearly 100 rare‑disease patient groups, biotech executives and investors wrote to President Trump, Health Secretary Robert F. Kennedy Jr., Medicare administrator Mehmet Oz and FDA Commissioner Marty Makary urging the administration to restore regulatory clarity at the...
Longer-Term Real-World Data Needed to Compare Leqembi and Kisunla Opposing Treatment Strategies for Alzheimer’s
Eisai/Biogen’s Leqembi and Eli Lilly’s Kisunla are the only FDA‑approved disease‑modifying Alzheimer’s therapies, but they follow opposite treatment models—continuous dosing versus a finite course after amyloid clearance. Four‑year data presented at AD/PD 2026 showed Leqembi delayed disease progression by roughly 9.8 months, with...
AbelsonTaylor Group Adds Irene Westcott as VP, Creative Director
AbelsonTaylor Group announced the appointment of Irene Westcott as Vice President and Creative Director. Westcott arrives with nearly two decades of copy‑focused experience delivering omni‑channel campaigns for pharmaceutical and healthcare brands. Her background includes leading award‑winning product launches, Subpart H/Accelerated Approval...
The Likely Evolution of Generic Players in the U.S. Life Sciences Market
The U.S. generic drug market, long driven by the Hatch‑Waxman Act, now supplies about 90% of prescriptions but only 10% of drug spend. Price erosion of 70‑80% within two years and the entry of six to eight competitors have turned...
US FDA Approves Higher-Dose of Biogen’s Genetic Disorder Drug
The U.S. FDA has approved a higher‑dose version of Biogen’s gene‑replacement therapy for a rare genetic muscle‑weakening disorder, likely spinal muscular atrophy. The new regimen starts with two 50 mg loading doses two weeks apart, followed by a 28 mg maintenance dose...
EU Regulator Backs Sanofi’s Injectable Version of Blood Cancer Drug
The European Medicines Agency has issued a positive opinion on Sanofi’s subcutaneous version of Sarclisa, a drug for multiple myeloma, citing late‑stage trials that proved non‑inferior efficacy to the intravenous formulation. If the European Commission follows the EMA’s recommendation, the...
AstraZeneca Drug Reduces Flare-Ups of Chronic Lung Disease in Late-Stage Trials
AstraZeneca’s experimental antibody tozorakimab cut moderate‑to‑severe COPD flare‑ups in two phase‑III trials, meeting its primary endpoint. The drug showed a statistically meaningful reduction across both current and former smokers, including those with varying lung damage. The positive data lifted AstraZeneca...
Pistoia Alliance Publishes First Best-Practice Framework for Ethical Social Media Use in Drug Development
The Pistoia Alliance has published a peer‑reviewed best‑practice framework guiding ethical use of social‑media listening in drug development. The framework, co‑authored by experts from Bayer, Roche, Boehringer Ingelheim, Chiesi and Semalytix, outlines standards for data anonymization, bias mitigation, and AI‑driven...
Med Ad Views Episode 06: From the Lab to Agency Leader, a Journey with Deborah Pan Dorner
Deborah Pan Dorner, a former MIT‑trained medicinal chemist, founded the healthcare communications agency Bond and Matter after a career in biotech research. The podcast episode explores how her scientific background shapes the agency’s data‑driven yet creative approach to pharma marketing....
Ogilvy Health Names Aimee Mosher Chief Client Officer
Ogilvy Health announced Aimee Mosher as its new chief client officer, effective immediately. Mosher arrives with over two decades of experience in healthcare marketing, having led teams at Science & Purpose, FCB Health, and Sudler & Hennessey. In her role...
AbbVie Named Official Pharma Partner of MLB, Expands ‘Striking Out Cancer’ on Opening Day
AbbVie has secured a multi‑year deal to become Major League Baseball’s Official Pharmaceutical Partner beginning with the 2026 season, extending its Striking Out Cancer initiative league‑wide. The program will donate $20 for every strikeout, up to $1 million per season, with...
Grifols Approves IPO of Its US Biopharma Business
Spanish plasma‑based drugmaker Grifols announced approval for a U.S. initial public offering of a minority stake in its U.S. biopharma business. The parent will keep its primary listing in Spain and retain majority control of the unit. Proceeds from the...
CVS Reaches Insulin Pricing Settlement with FTC
CVS Health announced a proposed settlement with the Federal Trade Commission concerning its insulin pricing practices. The agreement, negotiated by CVS’s pharmacy benefit manager Caremark, is modeled after the FTC’s recent deal with Express Scripts, a Cigna subsidiary. While the...
Novartis Pledges $480M to Expand China Presence, Following Eli Lilly and AstraZeneca
Swiss drugmaker Novartis announced a $480 million investment to expand its manufacturing and R&D footprint in China. The plan allocates about $218 million to upgrade its Beijing Changping facility, which can produce up to 3 billion tablets annually, and $262 million to expand its...
Ecnoglutide Approval Intensifies Competition in China GLP-1 Obesity Market
China's National Medical Products Administration approved Sciwind Biosciences' Ecnoglutide injection, marking the country's fifth GLP‑1 obesity therapy. The drug demonstrated a 15.4% average weight loss in the Phase III SLIMMER trial, with over 90% of participants achieving at least 5%...
Gilead Boosts Immunology Pipeline with over $2 Billion Buyout of Ouro Medicines
Gilead Sciences announced a deal exceeding $2 billion to acquire privately held biotech Ouro Medicines, bolstering its immunology and inflammation franchise. The purchase brings Ouro’s experimental antibody, OM336, which is in early‑stage trials for autoimmune disorders such as hemolytic anemia and...
FDA Warns of Seizure Risk with some Parkinson’s Drugs
The FDA’s recent safety alert warns that high‑dose levodopa/carbidopa regimens can provoke seizures when patients develop vitamin B6 deficiency. Fourteen post‑marketing cases, including two fatalities, involved doses exceeding 1,000 mg daily and featured focal‑onset seizures that generalized. Vitamin B6 supplementation halted...
Publicis Health and Talkspace Partner to Improve Treatment Adherence and Real-World Outcomes
Publicis Health announced a strategic partnership with Talkspace to embed Wisdo Health’s AI‑driven peer‑support platform into life‑sciences patient engagement programs. The collaboration adds personalized community groups and guided coaching to address social health gaps that drive medication non‑adherence. By detecting...
EyePoint Sues Rival Ocular Therapeutix, Alleging False Claims About Eye Drug
EyePoint Therapeutics filed a lawsuit in Massachusetts accusing rival Ocular Therapeutix of spreading false and misleading statements about EyePoint’s lead experimental eye drug, Duravyu. The complaint alleges defamation, commercial disparagement, consumer‑protection violations, and interference with business relationships. EyePoint seeks a...
Roche Ends Run for Muscular Atrophy Drug, Leaving Door Open for Competitors
Roche announced it will discontinue development of its anti‑myostatin antibody emugrobart for spinal muscular atrophy (SMA) after the Phase 2/3 MANATEE trial failed to demonstrate consistent muscle‑growth or motor‑function benefits. The study enrolled 259 patients and compared emugrobart plus Evrysdi against...
AstraZeneca to Build Cell Therapy Base, Innovation Center in Shanghai
AstraZeneca announced plans to construct a cell‑therapy manufacturing base and an innovation centre in Shanghai. The facilities will produce CAR‑T cancer treatments for China and broader Asian markets, positioning the company as the first global drugmaker with end‑to‑end cell‑therapy capabilities...
FDA’s Draft Guidance on Alternatives to Animal Testing in Drug Development
The FDA issued draft guidance to help drug developers validate new approach methodologies (NAMs) as alternatives to animal testing. The guidance outlines four validation principles—context of use, human biological relevance, technical characterization, and fit‑for‑purpose—to ensure NAM data are reliable for...
FTC Monitoring How Drug Companies React to Patent Cliff, Official Says
The U.S. Federal Trade Commission announced it is closely monitoring how pharmaceutical companies respond to the upcoming patent cliff affecting numerous blockbuster drugs. FTC antitrust director Dan Guarnera said the agency’s “laser focus” on healthcare will target any anticompetitive conduct...
Nexus Health Broadens Commercialization and Market Access Capabilities with Stratis Group Acquisition
Nexus Health, a consulting arm of The Lockwood Group, announced the acquisition of Stratis Group, a firm specializing in commercialization strategy, market access, HEOR, and analytics for life‑science clients. The deal expands Nexus Health’s service suite to cover forecasting, patient...
Gifthealth Launches Off-the-Shelf Solution for Most Favored Nation Pricing
Gifthealth unveiled an off‑the‑shelf platform that enables manufacturers to offer Most Favored Nation (MFN) pricing through direct‑to‑patient (DTP) programs. The solution leverages Gifthealth’s position as the nation’s largest DTP partner, handling over 90% of U.S. DTP volume and supporting more...
Why Women’s Health Is at an Inflection Point and Why Commercialization Models Must Advance
Women’s health funding has exploded, with investment rising over 300% since 2018 and tripling again by 2024, reflecting a clear market opportunity. Yet commercialization lags, leaving startups unable to scale, patients facing delayed access, and revenue potential unrealized. Fragmented care...
Havas Life London Identifies Stigma as a Structural Barrier in Rare Disease
Havas Life London’s new report reveals that stigma is a pervasive, structural barrier in rare disease care, affecting 89% of patients and caregivers surveyed. Healthcare settings account for the largest share of stigma incidents, with 42% reporting dismissed symptoms and...
Middle East War Disrupts Pharma Air Routes, Risks Cancer Drugs Supply
The war sparked by U.S. and Israeli strikes on Iran has shut key Gulf air hubs, disrupting temperature‑sensitive pharmaceutical shipments. Major cargo airports in Dubai, Abu Dhabi and Doha are closed, forcing drugmakers to reroute flights and rely on overland...
Eliquis Proves Safer than Xarelto for Patients with Deep Blood Clots
A head‑to‑head trial published in the New England Journal of Medicine compared Eliquis (apixaban) and Xarelto (rivaroxaban) in patients with deep‑vein thrombosis. The study found Eliquis significantly reduced major bleeding risk while maintaining equal efficacy in preventing clot recurrence. This...
AstraZeneca and Joshua Jackson Partner to Encourage Fans to Get Body Checked Against Cancer
AstraZeneca has partnered with actor Joshua Jackson and the Philadelphia Flyers mascot Gritty for the Get Body Checked Against Cancer campaign. The initiative leverages hockey’s "body check" metaphor to urge fans to discuss cancer‑screening options with their doctors. AstraZeneca highlighted...
J&J, AbbVie CEOs See Pay Spike to More than $30M
Johnson & Johnson chief Joaquin Duato and AbbVie chief Robert Michael each earned more than $30 million in 2025, pushing them into the top tier of pharma CEOs. Michael’s pay jumped 75% to $32.5 million, driven by $16.5 million in stock and option...
Lilly Issues Public Warning About Tirzepatide Compounded with B12
Eli Lilly has issued a public warning after testing revealed a significant impurity formed when tirzepatide is compounded with vitamin B12. The impurity’s health effects are unknown, and the company has alerted the FDA and urged patients to consult physicians....
AbelsonTaylor Group Announces the 2026 Class of nextgenerATion Summer Interns
AbelsonTaylor Group announced nine students and recent graduates for its 2026 nextgenerATion summer internship, a 10‑week paid program that immerses participants in healthcare advertising across pharma, biotech, medical devices, and wellness brands. Interns will rotate through creative, production, strategy, media,...
GoodRx Partners with Viatris to Offer up to 85 Percent Savings on Established Brand Medications
GoodRx announced a partnership with Viatris to slash prices on 17 of the latter’s established brand drugs, offering up to 85% off cash prices and as little as $0‑$4 for eligible commercially insured patients. The discounts are available at more...
Imre Names Fred Hickman III as Executive VP to Lead Account Services
Imre announced Fred Hickman III as executive vice president and group account lead, heading its Account Services division. Hickman arrives with 19 years of pharmaceutical marketing experience across rare disease, pediatrics, dermatology, ophthalmology, autoimmune, neurology and medical devices, most recently...
Cell and Gene Therapy Manufacturing Market to Skyrocket to $146B by 2032
Credence Research forecasts the global cell and gene therapy manufacturing market to surge from $19.3 billion in 2024 to $146.2 billion by 2032. The compound annual growth rate is estimated at 28.8%, propelled by rising demand for advanced therapies, expanding commercialization, and...
Lilly Issues Statement on CMS BALANCE Model for GLP-1 Drugs
Eli Lilly announced that the CMS CMMI BALANCE Model will cover its GLP‑1 obesity drugs—Zepbound, Mounjaro and, if approved, orforglipron—under Medicare Part D starting Jan 1 2027. After meeting the deductible, beneficiaries will pay a $50 monthly out‑of‑pocket cap, while pre‑deductible cost sharing is...
Amplifying Personal Moments in a Fragmented Media Landscape
Moon Rabbit’s managing director Jimmy Driscoll and VP Aimee Turner discussed their agency’s intimacy philosophy and how it shapes media integration in healthcare marketing. They highlighted the need to design personal, human‑centric moments amid a fragmented media environment. The conversation...
Novo Nordisk Expands U.S. Patient Access to FDA-Approved Semaglutide Medicines Through Hims & Hers
Novo Nordisk announced a partnership with telehealth provider Hims & Hers, allowing U.S. consumers to purchase FDA‑approved Ozempic and Wegovy at the same self‑pay prices as other digital platforms. The agreement eliminates compounded GLP‑1 offerings and enables patients to transition...
GSK Licenses Liver Disease Drug to Italy’s Alfasigma for up to $690 Million
British drugmaker GSK has licensed worldwide rights to its experimental liver‑disease drug linerixibat to Italy’s Alfasigma for up to $690 million. The agreement includes a $300 million upfront payment, a $100 million tranche upon U.S. approval, $20 million upon European and UK clearance, and...
Agilent to Acquire Biocare Medical in $950 Million All-Cash Deal
Agilent Technologies announced a $950 million all‑cash acquisition of privately held Biocare Medical, with closing expected by the fourth fiscal quarter of 2026. Biocare, based in California, supplies integrated tissue‑diagnostic products for cancer and infectious diseases and serves government and military...
Sino Biopharm Unit Licenses Blood Cancer Drug to Sanofi for up to $1.53 Bln
Sino Biopharm’s subsidiary Chia Tai Tianqing Pharmaceutical Group has signed an exclusive global licensing deal with Sanofi for its blood‑cancer drug rovadicitinib. The agreement provides Sanofi with worldwide rights to develop, manufacture and commercialize the oral JAK/ROCK inhibitor, and includes...
Lockwood Group Welcomes Total Health
The Lockwood Group announced it has acquired Total Health, the nation’s leading provider of free, in‑person oncology medical education. Total Health runs more than 60 CME programs each year for multidisciplinary cancer care teams, both virtually and on‑site. The deal...
